

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Horizon Health Limited

諾輝健康

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6606)

**RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
NON-COMPLIANCE WITH RULE 3.21 OF THE LISTING RULES;
AND
CONTINUED SUSPENSION OF TRADING**

The Board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of New Horizon Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from January 3, 2025, Dr. Donald Kwok Tung LI (“**Dr. LI**”) resigned as an independent non-executive Director and ceased to be a member of the audit committee of the Company (the “**Audit Committee**”).

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board hereby announces that Dr. LI has tendered his resignation as independent non-executive Director with effect from January 3, 2025 due to his other professional business commitments which require more of his time and devotion.

Upon his resignation, Dr. LI will no longer hold any position in the Group. Dr. LI has confirmed that he has no disagreement with the Board and there is no matter in respect of his resignation that would need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its gratitude and appreciation to Dr. LI for his contribution to the Company during his term of office as an independent non-executive Director.

NON-COMPLIANCE WITH RULE 3.21 OF THE LISTING RULES

According to Rule 3.21 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the Audit Committee shall comprise at least three members, and the majority of the Audit Committee must be the independent non-executive Directors. Following the resignation of Dr. LI, the number of members of the Audit committee would decrease from three to two, below the minimum number as required under Rule 3.21 of the Listing Rules.

The Company is endeavoring to identify a suitable candidate, being an independent non-executive Director, to act as an additional member of the Audit Committee to meet the requirements set out in Rule 3.21 of the Listing Rules as soon as practicable, and in any event within three months as required under Rule 3.23 of the Listing Rules, and will make necessary announcement as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the Company’s shares on the Stock Exchange has been suspended since March 28, 2024 and will remain suspended pending fulfilment of the Resumption Guidance (as defined in the announcement of the Company dated May 28, 2024).

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
New Horizon Health Limited
Mr. Naxin YAO
Chairman

Hong Kong, January 6, 2025

As at the date of this announcement, the Board comprises Mr. Naxin YAO as the Chairman and non-executive Director, Dr. Yiyou CHEN and Mr. Yeqing ZHU as executive Directors, and Mr. Danke YU, Mr. LAU Ngai Kee Ricky, Ms. NG Weng Sin and Ms. Jiangnan KONG as independent non-executive Directors.